Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 12/20 | 0.63 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.63 |
| ▸ | HIF1A | Q16665 | 6/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1413016 | 0.92 | P2RX7 (0.75) | P2RX7ABCB11HIF1A | |
| SCHEMBL1412855 | 0.89 | P2RX7 (0.60) | P2RX7ABCB11 | |
| SCHEMBL1412850 | 0.86 | P2RX7 (0.84) | P2RX7ABCB11HIF1A | |
| SCHEMBL1413027 | 0.85 | P2RX7 (0.59) | P2RX7ABCB11MEN1NPC1RAB9A | |
| SCHEMBL1413047 | 0.84 | P2RX7 (0.66) | P2RX7ABCB11HIF1AMEN1NPC1 | |
| SCHEMBL1412882 | 0.84 | P2RX7 (0.68) | P2RX7ABCB11HIF1AMEN1KMT2A | |
| SCHEMBL1412992 | 0.79 | P2RX7 (0.54) | P2RX7ABCB11 | |
| SCHEMBL1412901 | 0.77 | P2RX7 (1.00) | P2RX7ABCB11 | |
| SCHEMBL1412952 | 0.76 | P2RX7 (0.79) | P2RX7ABCB11 | |
| SCHEMBL1412902 | 0.76 | P2RX7 (0.55) | P2RX7ABCB11HIF1AMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1448535-B1 | BENZAMIDE AND HETEROARYLAMIDE AS P2X7 RECEPTOR ANTAGONISTS | PFIZER PROD INC (US) | 2011-03-16 | — | — | EP | disclosed |
| US-7235549-B2 | Benzamide, heteroarylamide and reverse amides | PFIZER INC. (US) | 2007-06-26 | — | — | US | disclosed |
| US-7214677-B2 | Benzamide, heteroarylamide and reverse amides | PFIZER INC. (US) | 2007-05-08 | — | — | US | disclosed |
| US-20060058302-A1 | Benzamide, heteroarylamide and reverse amides | PFIZER INC. | 2006-03-16 | — | — | US | disclosed |
| CN-1585755-A | Benzamide and heteroarylamide as P2X7 receptor antagonists | PFIZER PROD INC (US) | 2005-02-23 | — | — | CN | disclosed |
| EP-1448535-A1 | BENZAMIDE AND HETEROARYLAMIDE AS P2X7 RECEPTOR ANTAGONISTS | Pfizer Products Inc. (US) | 2004-08-25 | — | — | EP | disclosed |
| US-20030186981-A1 | Benzamide, heteroarylamide and reverse amides | PFIZER INC. | 2003-10-02 | — | — | US | disclosed |
| WO-2003042191-A1 | BENZAMIDE AND HETEROARYLAMIDE AS P2X7 RECEPTOR ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2003-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030186981-A1 | Benzamide, heteroarylamide and reverse amides | P2RX7, P2RX5, P2RX2 | P2RX7 1/4885ABCB11 866/4885HIF1A 59/4885 |
| US-20060058302-A1 | Benzamide, heteroarylamide and reverse amides | P2RX7, P2RX5, P2RX2 | P2RX7 1/4885ABCB11 443/4885HIF1A 149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.